Related Experiment Videos
[Laboratory and clinical studies on cefdinir in pediatric field]
1Department of Pediatrics, Aomori Prefectural Central Hospital.
Insights
Cefdinir (CFDN) demonstrates excellent efficacy and safety in pediatric bacterial infections. This oral antibiotic achieved a 100% clinical efficacy rate and a 94.7% bacteriological eradication rate in children.
Area of Science:
- Pediatric Pharmacology
- Infectious Diseases
- Antibiotic Therapy
Background:
- Cefdinir (CFDN) is an oral antibiotic.
- Pediatric bacterial infections require effective and safe treatment options.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical efficacy of cefdinir (CFDN) in children.
- To assess the safety profile of cefdinir (CFDN) in pediatric patients.
Main Methods:
- Pharmacokinetic analysis of cefdinir (CFDN) plasma levels and urinary excretion in 10 children (7-13 years).
- Clinical efficacy evaluation in 23 children with bacterial infections receiving cefdinir (CFDN) orally (3.3-6.3 mg/kg TID).
- Bacteriological eradication rates and side effect monitoring were assessed.
Main Results:
- Plasma concentrations peaked at 2-4 hours post-administration.
- An 8-hour urinary recovery rate of 18.8% was observed.
- 100% clinical efficacy and 94.7% bacteriological eradication rates were achieved.
- Adverse events were minimal, including mild loose stool and transient elevation of liver enzymes.
Conclusions:
- Cefdinir (CFDN) is a safe and effective oral antibiotic for treating bacterial infections in children.
- The drug exhibits favorable pharmacokinetic properties and a high success rate in pediatric patients.
Abstract:
Pharmacokinetic and clinical studies on cefdinir (CFDN) capsule and fine granules in children were performed and the following results were obtained. 1. Plasma level and urinary excretion of CFDN were determined in 10 children with ages 7 to 13 years given single doses of 2.3 to 7.5 mg/kg. Six of the 10 children received the drug orally before meal and the other 4 after meal. Plasma concentration peaked at 2 to 4 hours in the children administered the drug before meal, and at 3 to 4 hours in those given the drug after meal. The 8-hour urinary recovery rate was 18.8%. 2. Clinical efficacies were evaluated in 23 children with bacterial infections. The children were given the drug orally at dose levels of 3.3 to 6.3 mg/kg 3 times a day. Clinical effects of CFDN were excellent in 7 and good in others, hence the overall clinical efficacy rate was 100%. 3. Bacteriologically, 18 of the 19 strains of causative organisms identified were eradicated, with an overall bacteriological eradication rate of 94.7%. 4. As for side effects, loose stool was observed in 1 case, but it disappeared in a few days. In laboratory tests a slight elevation of GOT and GPT were observed in 1 case, but no additional treatment was needed. 5. CFDN is a useful oral antibiotic for the treatment of bacterial infections in pediatric field.